Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Bo Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4456-7303; OpenAlex author ID A5100374429. Sources: OpenAlex.

Their work

Papers
8 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 8

  1. Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. Co-author DOI 10.1172/jci.insight.181873↗
  2. Comprehensive Bioinformatics Analyses and Experimental Validation of the Cell Cycle Related Protein SAPCD2 as a New Biomarker and Potential Therapeutic Target … First author DOI 10.2147/jir.s501850↗
  3. The molecular mechanism underlying KRAS regulation on STK31 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.16286↗
  4. A novel aging-associated lncRNA prognostic signature for predicting immunotherapy and chemotherapy response in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-3431528/v1↗
  5. Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases. First author DOI 10.1016/j.ijsu.2022.106786↗
  6. NMIIA promotes tumor growth and metastasis by activating the Wnt/β-catenin signaling pathway and EMT in pancreatic cancer. Co-author DOI 10.1038/s41388-019-0806-6↗
  7. The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer. First author DOI 10.1186/s12943-017-0624-9↗
  8. Tumour cryoablation combined with palliative bypass surgery in the treatment of unresectable pancreatic cancer: a retrospective study of 142 patients. Last author DOI 10.1136/pgmj.2010.098350↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Suizhi Gao · 2 shared papers, 2022–2025 · strength 0.32
  2. Kailian Zheng · 2 shared papers, 2022–2025 · strength 0.32
  3. Shiwei Guo · 2 shared papers, 2022–2025 · strength 0.32
  4. Xiaoyi Yin · 2 shared papers, 2022–2025 · strength 0.32
  5. Xiaohan Shi · 2 shared papers, 2022–2025 · strength 0.32
  6. Yuting Liu · 1 shared paper, 2025 · strength 0.24
  7. Jian Qi · 1 shared paper, 2025 · strength 0.24
  8. Chi Han Li · 1 shared paper, 2024 · strength 0.23
  9. Chi Hin Wong · 1 shared paper, 2024 · strength 0.23
  10. Yuting Liu · 1 shared paper, 2024 · strength 0.23
  11. Stephen Lam Chan · 1 shared paper, 2024 · strength 0.23
  12. Yangchao Chen · 1 shared paper, 2024 · strength 0.23
  13. Li Yan · 1 shared paper, 2023 · strength 0.19
  14. Yuling Chen · 1 shared paper, 2023 · strength 0.19
  15. Yuanchun Ye · 1 shared paper, 2023 · strength 0.19
  16. Lingyu Zhu · 1 shared paper, 2025 · strength 0.19
  17. Xiongfei Xu · 1 shared paper, 2025 · strength 0.19
  18. Yunguang Li · 1 shared paper, 2025 · strength 0.19
  19. Dong Gao · 1 shared paper, 2025 · strength 0.19
  20. Gang Jin · 1 shared paper, 2025 · strength 0.19
  21. Eric Tran · 1 shared paper, 2025 · strength 0.19
  22. Yao Zong YUAN · 2 shared papers, 2017–2019 · strength 0.18
  23. Dong Li · 2 shared papers, 2017–2019 · strength 0.18
  24. Pingting Zhou · 2 shared papers, 2017–2019 · strength 0.18
  25. Xiangui Hu · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.